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AbstrAct
Expression of the antimicrobial peptide hCAP18/LL-37 is associated to malignancy 
in various cancer forms, stimulating cell migration and metastasis. We report that 
LL-37 induces migration of three cancer cell lines by activating the TRPV2 calcium-
permeable channel and recruiting it to pseudopodia through activation of the PI3K/
AKT pathway. Ca2+ entry through TRPV2 cooperated with a K+ efflux through the BKCa 
channel. In a panel of human breast tumors, the expression of TRPV2 and LL-37 was 
found to be positively correlated. The D-enantiomer of LL-37 showed identical effects 
as the L-peptide, suggesting that no binding to a specific receptor was involved. LL-37 
attached to caveolae and pseudopodia membranes and decreased membrane fluidity, 
suggesting that a modification of the physical properties of the lipid membrane bilayer 
was the underlying mechanism of its effects.
IntroductIon
The peptide LL-37 is released from the C-terminus 
of the Human Cathelicidin Antimicrobial Protein hCAP18. 
Apart from its antimicrobial activities, it also induces 
proliferation and migration of epithelial cells or stimulates 
angiogenesis by a direct effect on endothelial cells 
(for review, [1]).
In multiple cancer forms [2, 3] LL-37 was found to 
stimulate both proliferation and migration of cancer cells, 
thus contributing to cancer development and progression. 
LL-37 was proposed to promote cell migration through 
stimulation of FPRL-1 receptor, a Pertussis toxin-
sensitive G protein coupled receptor (GPCR) in cell lines 
from ovarian cancer and human skin [4]. In pancreatic 
cancer cell lines the ATP-gated purinergic receptor P2X7 
was additionally required to induce cell invasion [5]. In 
several other cell lines LL-37 activated different tyrosine 
kinase receptors and ERK1/2 and AKT signaling [6–8]. 
In the weakly invasive MCF7 breast cancer line, LL-37 
increased cell mobility and metastasis development in a 
mouse model without involving FPRL-1 [3]. Although the 
activation of MAPK signaling via ERBB2, and/or IGFR 
[9] was observed in this model system, the mechanism 
underlying this induction was not identified. Taken 
together, LL-37 has the ability to activate multiple plasma 
membrane receptors of unrelated structures, and to induce 
a pro-metastatic phenotype.
Remodeling of Ca2+ homeostasis is an important 
modifier of migratory and invasive activities in cancer 
cells [10–12]. In non-excitable cells, Ca2+ entry mostly 
occurs through non-voltage-gated Ca2+ channels located in 
the plasma membrane. Some Ca2+-permeable channels can 
be activated after binding their ligand, such as the ATP-
gated P2X receptors [13]. Store-Operated Ca2+ Channels 
(SOCs) are activated by preliminary release of internal 
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Ca2+ stores that induce Store-Operated Ca2+ Entry (SOCE). 
In comparison, Store-Independent Ca2+ Channels (SICs) 
can be stimulated without the release of internal Ca2+ 
stores. These mechanisms are supposed to mainly activate 
the channels of the TRP superfamily and the Orai family 
[14]. Some of these channels are constitutively open at 
the plasma membrane contributing to basal migration and 
invasivity in breast and prostate cancer cells [14]. Ca2+ 
entry can activate Ca2+-activated K+ channels leading to 
membrane hyperpolarization, thus increasing the driving 
force for Ca2+ across the plasma membrane [15]. To date, 
two K+ channels (hEag1 and SK3) that potentiate Orai1-
dependent constitutive Ca2+ entry have been reported to 
stimulate cancer cell migration [16] and metastasis [17]. 
LL-37 induces Ca2+ mobilization in mast cells [18] 
and in submandibular gland cells [19]. The only Ca2+ 
channel identified so far as activated by LL-37 is the 
P2X7 receptor channel. In a transgene HEK293 model 
system [20], Ca2+-influx through P2X7 increased cell 
proliferation. 
The goal of this study was therefore to investigate 
whether the effects of LL-37 on cancer cell migration 
might be linked to regulation of intracellular Ca2+ 
concentration, to identify plasma membrane Ca2+ channels 
activated by LL-37 and potentially cooperating K+ 
channels, and to determine their mechanism of activation 
by LL-37.
results
ll-37 binds to the plasma membrane and 
induces ca2+ entry and cell migration
We initially focused on the highly malignant 
cancer cell line MDA-MB-435s, for which several Ca2+-
permeant channels had already been characterized as 
mediators of cell migration [17]. In accordance with 
our previous findings in MCF7 cells [3], LL-37 induced 
cell migration of MDA-MB-435s at 10 µg/ml (≈ 4 fold 
increase, p < 0.001, Figure 1A). A scrambled peptide 
with identical content in amino acids showed no effect. 
Lanthanum (La3+), a non-specific blocker of Ca2+ channels, 
significantly reduced the cell migration by 88% (p < 0.01).
As shown by Ca2+ spectrofluorimetry in presence of 
2 mM external Ca2+ (Figure 1B, left panels), intracellular 
Ca2+ increased after few seconds upon treatment with 
LL-37. This was significantly decreased by incubation 
with La3+ (−86%, p < 0.01, Figure 1B, left panel). A 
modification of the protocol [17] permitted us to measure 
the constitutive entry of extracellular Ca2+ through 
active Ca2+channels of the plasma membrane, without 
depletion of the intracellular Ca2+ stores. Compared to 
control condition, which showed a Ca2+ influx through 
constitutively open channels, LL-37 substantially 
increased this Ca2+ entry (Figure 1B, right panel). 
A peptide with opposite chirality ((D)-LL37) 
presented identical activities in increasing internal 
Ca2+ and migration of MDA-MB-435s (Figure 1C). 
These results suggested that specific peptide-protein 
interactions were not required and that the cellular effects 
of LL-37 might originate from its capacity to attach to the 
membrane. 
These findings prompted us to determine where 
LL-37 bound to the cell. The initial immunofluorimetric 
analysis revealed that LL-37 attached to the plasma 
membrane (Figure 2A, LL-37 on non-permeabilized 
cells), but was partially endocytosed by the cell after 
5 min of incubation (Figure 2A, LL-37 on permeabilized 
cells). To follow the fate of LL-37 in the living cell, the 
Cy5 fluorochrome was conjugated to a peptide modified at 
position 26 by an azido-functionalized amino acid. Using a 
bioorthogonal strain-promoted azide/alkyne cycloaddition 
reaction, conjugation could be conducted either before 
or after application of the peptide to the cells. Both 
alternatives resulted in identical localization of the peptide 
in the cell (data not shown). We had previously verified 
that an amino acid exchange at this position (LL-37 
Asp26Ile) did not change its effect (data not shown) on 
cell migration and activation of Ca2+ influx. Confocal 
microspectral analysis revealed a significant blue shift by 
3 nm on the emission spectrum when Cy5fluo-LL-37 was 
localized on the surface of the cell (green spectrum and 
green zones on Figure 2B), compared to the same peptide 
in culture medium (red spectrum and red zones, Figure 2B). 
This spectral shift is characteristic for a decreased polarity 
environment of the fluorochrome [21]. This suggested 
that LL-37 bound to the plasma membrane, and remained 
located to a membrane after intracellular uptake of the 
peptide. Sodium azide (1%), a potent inhibitor of ATP-
driven endocytosis, did not prevent Cy5fluo-LL-37 
from binding to the cell but blocked its internalization 
(Figure 2B, bottom right). 
Immunogold-labeled anti-LL-37 was located at 
the surface of pseudopodia and invaginated structures 
characteristic of caveolae as assayed in immunoelectron 
microscopy (Figure 2C, left and middle panels), thus 
confirming the association of LL-37 to membrane 
structures. Apart from these structures, no signal 
was found on the remaining extracellular membrane. 
Intracellular signals in cells treated with LL-37 for 5 min 
remained exclusively at membranes of the caveosomes 
(Figure 2C, right panel) without any evidence of free 
cytoplasmic LL-37. 
The activity of membrane-associated proteins and 
signal transduction is influenced by the organization of the 
plasma membrane, signaling being more active in rigid 
nanodomains (such as lipid rafts) than more fluid phases 
[22, 23]. We investigated the effect of LL-37 on the plasma 
membrane fluidity with Laurdan, a lipid-packaging sensor 
[24, 25]. The generalized polarization (GP) value, which 
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Figure 1: ll-37 induces ca2+ influx that promotes migration of MDA-MB-435s cells. (A) LL-37 induced migration is blocked 
by La3+. The level of induction by LL-37 in presence and absence of 100 µM LaCl3 (La), and scrambled peptide (scr) is displayed relative to 
cell migration (Ctl) without LL-37. n ≥ 8. (b) LL-37 increases intracellular Ca2+. Upper graphs showing the time course of fura-2 fluorescence 
ratio detected at 510 nm with both excitations at 340 and 380 nm. Lower graphs, compilations of experiments where the fluorescence ratio 
is normalized against the basal level of each experiment. Left panels display results obtained using a constant external 2 mM Ca2+. The 
dotted line shows the normalized basal level and La3+ inhibitory effect is indicated relative to LL-37 alone (n ≥ 6). Right panels display 
results obtained by shifting the extracellular Ca2+ from 0 to 2 mM after 20s of measurement without depletion of the intracellular store. Ctl : 
fluorescence ratio without LL-37 after applying of 2 mM Ca2+, LL-37 : fluorescence ratio with LL-37 after applying of 2 mM Ca2+. n =  10. 
(c) (D)-LL-37 induces cell migration (left panel, n = 10). By shifting the extracellular Ca2+ from 0 to 2 mM, (D)-LL-37 increases fura-2 
fluorescence ratio detected at 510 nm with excitations at 340 and 380 nm.(right panel, n = 7).
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Figure 2: LL-37 binds to pseudopodia and caveolae membranes altering their fluidity. (A) LL-37 attachment to plasma 
membrane and its internalisation after 5 min. Detection of LL-37 by immunofluorescence performed on non-permeabilized and 
permeabilized MDA-MB-435s cells treated with LL-37 for 5 min. DAPI is used for nuclear staining. (b) Localisation of LL-37 in an 
apolar environment at and inside the MDA-MB-435s cells. Labelling of LL-37 using azido-functionalized LL-37 (LL-37-Asp26Ile) 
coupled with Cy5 fluorochrome (Cy5fluo-LL-37) detected by confocal microspectrometry. The graph shows the characteristic emission 
(Cy5fluo-LL-37), measured in a apolar (green) environment when attached to the cell or a polar (red) environment when located outside. 
Images below show the superposition of a visible cell image with its Cy5fluo-LL37 spectral card after 5 min, in absence (left) or presence 
(right) of 1% NaN3. (c) Localisation of LL-37 on pseudopodia and caveolae membranes in the MDA-MB-435s cell by immunoelectron 
microscopy. Cells were incubated with LL-37 for 5 min, fixed and then immunogold labelling was performed. Identification of pseudopodia 
(left, structures indicated with a P) and caveolae (mid, indication with (C) at the extracellular membrane, and of caveosome membranes 
at the intracellular membrane (right, indicated with Cs). (d) Increase of the generalized polarisation value of by LL-37. The upper graph 
shows an emission spectrum of the Laurdan probe before (1) and after (2) treatment of MDA-MB-435s cells with LL-37. The lower graph 
shows the time course of GP measurement as described in materials and methods, arrows with numbers (1) and (2) indicating when the 
emission spectrum (upper graph) was recorded.  Right diagram shows the compilation of ΔGP value after addition of scrambled (scr), 
(L)-LL-37 or (D)-LL-37 peptides (n ≥ 8).
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permits a quantitative assessment of the membrane order, 
increased by 2.5% (from 0.4 to 0.41) after addition of 
LL-37, indicating a decrease of membrane fluidity 
(Figure 2D). In comparison, lysophosphatidylcholine 
at 100 µM, known to increase membrane fluidity [26], 
reduced the GP value by 10% (data not shown). 
To assess the effect of LL-37 on membranes of 
different compositions and phase states [27], the GP 
values of large unilamellar vesicles were determined after 
addition of increasing concentrations of LL-37. LL-37 
decreased membrane fluidity for all conditions assayed 
(supplementary Figure S1).
ll-37 recruits trPV2 to pseudopodia through 
the PI3K pathway
The Orai1/SK3 channel complex has been 
characterized as a source for a constitutive Ca2+ entry 
in MDA-MB-435s cells [17]. Orai1 suppression by 
RNA interference reduced the constitutive Ca2+ entry, 
however at a similar rate during absence or presence of 
LL-37 (supplementary Figure S2A). Orai1 thus appeared 
active irrespective of the presence of LL-37, and thus not 
responsible for the additional Ca2+ entry caused by LL-37. 
When expressed in HEK293 cells, P2X7 has been reported 
to act as a Ca2+ permeant channel activated by LL-37 [20]. 
P2X7 is fully functional in MDA-MB435s cells, in which 
it promotes cell migration and invasiveness [28, 29]. 
However, KN62, an antagonist of P2X7, did not prevent 
the Ca2+ entry induced by LL-37 (data not shown). 
In order to identify other putative targets for 
LL-37, we screened the expression of Ca2+ channels 
previously identified as involved in various cancer cell 
properties [11]. The TRPV2 and TRPC1 channels showed 
a notably high expression (supplementary Figure S3). 
Suppression of TRPC1 by RNA interference had no 
effect on LL-37 induced Ca2+ entry (supplementary 
Figure S2B). In contrast, the suppression of TRPV2 
by RNA interference resulted in significant reduction 
of LL-37 induced cell migration and Ca2+ entry 
(Figure 3A). At basal conditions, siTRPV2 reduced 
constitutive Ca2+ entry by 27%, whereas the induction 
by LL-37 was reduced by 41% (p < 0.01, Figure 3A, 
upper and middle panels). 
In cells treated with siTRPV2, basal migration 
without peptide was reduced (−45%) but clearly at 
less extent than LL-37-stimulated migration. The pro-
migratory effects of (D)- and (L)-peptides were both 
suppressed at similar extent (−71% and −79% respectively, 
p < 0.001, Figure 3A, lower panel), confirming their 
identical mechanism of activity. 
As TRPV2 has been reported activated by PI3K/
AKT signaling [30, 31] we investigated whether LL-37 
could induce this pathway. Western blot analysis revealed 
that AKT phosphorylation was induced by LL-37, and 
blocked by the PI3K inhibitor LY2940042 (Figure 3B, 
upper panel). In agreement with this, the PI3K inhibitor 
Wortmannin partially inhibited LL-37 induced Ca2+ entry 
(−20% p < 0.01, Figure 3B, middle panel). Both inhibitors, 
Wortmannin and LY2940042, strongly reduced LL-37 
induced cell migration (−68% and −58%, respectively, 
p < 0.01, Figure 3B, lower panel). 
Previous experiments in MCF7 cells had 
demonstrated that LL-37 could activate ERK/MAPK 
signaling [3]. In MDA-MB-435s, ERK was found 
constitutively phosphorylated, and the ERK inhibitor 
UO126 did not block LL-37-stimulated migration (data 
not shown).
TRPV2 has been shown to be translocated to the 
plasma membrane upon activation [31], or being localized 
to the membrane and providing constitutive Ca2+ entry 
[32]. We studied the location of TRPV2 by fluorescence 
microscopy on immunostained MDA-MB-435s cells. In 
permeabilized unstimulated cells, TRPV2 was located 
predominantly intracellularly (data not shown), but a weak 
spotted staining was observable on the membrane surface 
at non-permeabilized cells (Figure 4A). This localization 
is in accordance with the constitutive Ca2+ entry that was 
suppressed by RNA interference (Figure 3A). Upon a 
5-min long LL-37 treatment TRPV2 labeling strongly 
increased at the plasma membrane, suggesting it was 
translocated from intracellular compartments. Inhibitors 
of AKT/PI3K (LY2940042 or Wortmannin) prevented this 
translocation to the plasma membrane. Identical results 
were obtained when (D)-LL-37 was used instead of its 
natural (L)-enantiomer (Figure 4A). 
We performed immunoelectron microscopy to 
precise TRPV2 cellular localization. In unstimulated 
MDA-MB-435s cells, TRPV2 staining was predominantly 
intracellular, in proximity of the plasma membrane and 
associated with membrane structures including Golgi 
vesicles. Some spots were also observed in pseudopodia. 
Upon LL-37 treatment, the staining at pseudopodia was 
dramatically increased, at the expense of the intracellular 
compartment (Figure 4B). Taken together, these results 
are consistent with a membrane translocation of TRPV2 
to specialized structures such as pseudopodia upon LL-37 
exposure.
the bKca channel cooperates with trPV2
Since the driving force of Ca2+ entry can be promoted 
by K+ efflux [33], we performed an initial study using a 
tetraethylammonium (TEA) as non-selective inhibitor of 
K+ channels. TEA reduced the intracellular Ca2+ increase 
induced by LL-37 (supplementary Figure S2C) suggesting 
a contribution of K+ channels. Previous experiments by 
Chantôme et al. [17] have shown that constitutive Ca2+ 
entry in MDA-MB-435s cells is supported by the SK3 
channel which was removed by transformation with 
a lentivector expressing short hairpin RNA (shRNA) 
against SK3. In this shRNA-SK3 cell model, the Ca2+ 
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entry induced by LL-37 was weakly decreased, suggesting 
that this channel was not deeply activated by LL-37 
(supplementary Figure S2D). We therefore investigated 
the large conductance Ca2+ activated K+ channel (BKCa), 
which is also expressed in these cells [34]. Figure 5A is 
a typical example of current-density voltage relationships 
showing an increase of the amplitude of an outward 
current upon LL-37 treatment. This outward current, 
measured at the membrane voltage of 0 mV (Figure 5A, 
right panel), was increased by LL-37, reaching a 2.5 
fold induction. This induction was significantly reduced 
(−77%) by pretreatment with iberiotoxin (Ibtx), suggesting 
BKCa as responsible for the current. 
In correspondence, Ibtx reduced both Ca2+ 
entry (−16%, Figure 5B) and cell-migration 
(−40%, Figure 5C) induced by LL-37. The constitutive 
Ca2+ entry remained unchanged by Ibtx. Interestingly, when 
combining BKCa inhibition by Ibtx and the suppression 
of TRPV2 by RNA interference, no further reduction of 
the activities by LL-37 was obtained. This suggested that 
the activities of both channels were linked to each other 
and not on unrelated pathways. Confocal microscopy 
Figure 3: ll-37 increases PI3K/AKt signaling and ca2+-influx through TRPV2, promoting MDA-MB-435s cell 
migration. (A) RNA interference against TRPV2 reduces Ca2+ entry and cell migration caused by LL-37. Upper panel: time course of 
intracellular Ca2+ by shifting the extracellular Ca2+ from 0 to 2 mM after 20s on cells treated with siRNA against TRPV2 (siV2) or control 
siRNA (siCt) in presence and absence of LL-37. The mid panel displays compilation of results. Fura-2 fluorescence ratio is normalized 
against the basal level of each individual experiment. The dotted line shows the normalized basal level and the inhibitory effect of siV2 
is indicated relative to siCtl with LL-37 (n = 8). Bottom panel: (L-)LL-37- and (D)-LL-37 induced (n ≥ 8) cell migration is suppressed by 
TRPV2 siRNA. Values are displayed relative to the migration of cells induced by LL-37. FCS is used to control cell mobility in presence of 
siRNAs (n = 3). (b) PI3K/AKT pathway activation by LL-37 contributes to Ca2+ entry and cell migration. Upper panel: Western blot analysis 
of AKT phosphorylation in MDA-MB-435s protein extracts treated or not with LL-37 and/or PI3K inhibitor LY2940042 (1 µM). Blots 
were reprobed with a panAKT antibody. Mid panel: Ca2+ entry by LL-37 is decreased in presence of PI3K inhibitor Wortmannin (n ≥ 10). 
Condition and evaluation as above. Bottom panel: Suppression of LL-37 induced cell migration in presence of 1 µM LY294002 (n = 8) 
or 100 nM Wortmannin (n = 5). Values are displayed relative to the migration of cells induced by LL-37.
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located BKCa at the plasma membrane, and this 
remained apparently unaltered by treatment with LL-37 
(Figure 5D, left panel). Using electronic microscopy 
BKCa immunogold signals appeared intracellular and on 
the membranes of pseudopodia (Figure 5D, right panel). 
ll-37 and trPV2 cooperate in breast tumors 
and cell cancer lines 
To investigate whether TRPV2 and LL-37 
may be connected in breast cancer, we performed an 
immunohistochemical study on sections of 101 breast 
tumors (Figure 6A). Staining for LL37 and TRPV2 was 
found in 60 and 42 invasive carcinomas, respectively. The 
signal of both was significantly correlated (P < 10−4). In 
the group of LL-37-positive tumors, the number of tumors 
positively staining for TRPV2 was clearly enriched. 
An even more striking correlation was found in LL-37 
negative tumors, of which only 4 of 41 tumors expressed 
TRPV2 in absence of LL-37.
Based on such a tight correlation, we hypothesized 
that the expression of LL-37 might directly influence 
the level of TRPV2. Since MDA-MB-435s cells highly 
expressed TRPV2, we studied the MCF7 cell line, 
which showed low basal expression of TRPV2. We 
created a transgenic derivative by stable transfection 
with an expression vector for hCAP18/LL-37. 
Immunohistochemistry revealed an increased signal 
for TRPV2 as well (Figure 6B). Further analysis by 
qRT-PCR did not show any altered transcription level, 
indicating that the influence of LL-37 on TRPV2 levels 
was posttranscriptional (data not shown). 
In order to confirm whether the relation between 
LL-37 and TRPV2 held true on the functional level as 
well, we performed a migration study on MCF7, and in 
addition on the high malignant MDA-MB-231 breast 
cancer cell line. LL-37 induced migration in both cell 
lines (Figure 6C) as well as the (D)-enantiomer (data not 
shown). In both cases this induction was suppressed by 
RNA interference against TRPV2 (Figure 6C). 
dIscussIon
We have shown that LL-37 binds to the plasma 
membrane, especially in caveolae and pseudopodia. 
This leads to increase intracellular Ca2+ and cell 
Figure 4: LL-37 induces PI3K-dependent TRPV2 translocation to pseudopodia membranes. (A) Immunofluorescence 
analysis on non-permeabilized cells revealing the translocation of TRPV2 to the plasma membrane by (L)-LL-37 and (D)-LL-37 peptides 
and blocked by PI3K inhibitor LY2940042 (1 µM). (b) Localisation of TRPV2 by immunoelectron microscopy. The location of immunogold 
signals, intracellularly and sporadically at pseudopodia (P) before and accumulated at pseudopodia after 5 min of cell treatment with LL-37, 
is indicated with arrows.
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Figure 5: TRPV2 cooperates with BKCa. (A) BKCa inhibitor IbTx decreases LL-37 induced outward potassium current on MDA-
MB-435s cells. Left panel shows examples of currents obtained with I-V protocol on MDA-MB-435s cells in presence (LL-37) or absence 
(PSS) of the peptide. Currents were measured for each voltage clamp (V) from −90 at +80 mV during 500 ms, every 10 mV increase. Mid 
panel displays a representative Current-Voltage curves which shown the current density-voltage relationships obtained using ramp protocol 
recorded in PSS or in presence of LL-37 and with or without pretreatment with 100 nM Ibtx. Right panel represents the compilation of 
the outward current at the membrane voltage at 0 mV normalized to PSS condition (5 < n < 12). (b) IbTx decreases LL-37 induced Ca2+ 
influx without additional effect of anti-TRPV2 siRNA (siV2). Fura-2 probe is used to measure Ca2+ influx after 2 mM Ca2+ application as 
described in material and methods. The effects of LL-37 and IbTx (100 nM) are evaluated on MDA-MB-435s cells transfected with siRNA 
against TRPV2 or control siRNA (siCt). Fura-2 fluorescence ratio is normalized against the basal level of each individual experiment. The 
dotted line shows the normalized basal level and the inhibitory effect of siV2 and/or IbTx is indicated relative to siCtl with LL-37 (n = 13). 
(c) IbTx decreases LL-37 induced cell migration without additional effect of anti-TRPV2 siRNA (siV2). The inhibitory effect of siV2 and/
or IbTx is indicated relative to siCtl with LL-37 (n = 8). (d) BKCa membrane location remains unaltered after application of LL-37. Left 
panels show the detection of BKCa by immunofluorescence performed on non-permeabilized MDA-MB-435s cells treated or not with 
LL-37 for 5 min. DAPI is used for nuclear staining. Right panels show the localisation of BKCa on pseudopodia (P) and intracellularly by 
immunoelectron microscopy. The location of immunogold signals, intracellularly and at pseudopodia (P) is indicated with arrows.
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migration through activation of the Ca2+ channel TRPV2 
predominantly located in pseudopodia. Moreover, LL-37 
induces TRPV2 recruitment at the plasma membrane by a 
PI3K/AKT-dependent pathway. Figure 7 summarizes our 
data with the activated channels involved for migration, 
their cellular location as well as the mechanisms of action 
we propose for LL-37. 
In accordance with results of two previous studies 
[6, 20], both (D)- and (L)- enantiomers presented identical 
activities. As mentioned above, previous studies have 
shown a variety of receptors being activated by LL-37, 
however without detailing evidence for a conventional 
receptor-ligand interaction. It needs to be considered 
whether some of these observations can equally be 
explained by an indirect activation of the respective 
receptors through interaction of LL-37 with the cell 
membrane.
Both increase and decrease of membrane fluidity 
can activate signaling pathways on the same cell [35]. 
Fluidity alterations in either direction have been observed 
in cancer, depending of the cancer type and stage of 
carcinogenesis and no general trend being discerned [36]. 
Epithelial-to-mesenchymal transition and cell migration 
of breast cancer lines are reported to be suppressed by 
globally decreasing membrane fluidity [37, 38]. On the 
migrating cell, however, membrane rigidity was shown 
locally increased at leading edge and retracting tail 
[39]. The latter observation is in line with our findings, 
especially when considering that LL-37 acts locally on 
pseudopodia, structures related to cell migration. 
We have localized LL-37 at the cellular membrane 
specifically of caveolae and pseudopodia, and remaining 
at the caveosome after its internalization. While this 
manuscript was being revised, the binding of LL-37 in 
complex with lipopolysaccharides and their endocytosis at 
lipid rafts was published to require sulfated proteoglycans 
[40] on the cell surface, which may have served to guide 
the attachement of cationic LL-37 attachment. 
Figure 6: LL-37 and TRPV2 cooperate in cell cancer lines and breast tumors. (A) Immunohistochemical analysis of breast 
tumors reveals coexpreussion of LL-37 and TRPV2. Left panel: representative example of sections from two breast carcinomas showing 
strong signals for both LL-37 and TRPV2 staining, or low immunoreactivity for either of them. Right panel displays the evaluation of 101 
breast tumors, and revealing significant coexpression of LL-37 and TRPV2 (chi-square: p < 10−4). (b) Immunohistochemistry on the MCF7 
cell line, revealing an increased signal for TRPV2 in cells with transgenic expression of hCAP18/LL-37. (c) RNA interference against 
TRPV2 decreases LL-37 induced cell migration of MCF7 (left panel) and MDA-MB-231 (right panel) cells. 
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The peptide forms an amphipathic helix, attaching on 
the membrane surface in form of a carpet [41, 42]. LL-37 
binding can induce a mechanical stress on the plasma 
membrane [43]. This may explain how TRPV2, known 
to be an osmo- [44] and mechanosensor [45, 46] channel, 
is activated. Mechanical stress has been shown to locally 
increase PI3K activity at the sites of the stress, required to 
recruit TRPV2 to the membrane [46], and to activate the 
channel [32]. We found LL-37 attached to both caveolae 
and pseudopodia, whereas TRPV2 was exclusively 
directed to the pseudopodia. The binding of LL-37 to the 
caveolae and its modification of the membrane structure 
may activate the receptors localized therein [39], and 
lead to AKT signaling that addresses the channel to 
pseudopodia. Whether the localization of LL-37 to 
caveolae and/or pseudopodia directs the translocation of 
TRPV2 can presently not be determined.
It should be mentioned that part of TRPV2 was 
already located in pseudopodia in basal conditions, which 
explains its contribution to the constitutive Ca2+ entry and 
migration without stimulation by LL-37.
The inhibition of the BKCa channel decreased Ca2+ 
entry and cell migration, however, without an additive 
effect when both BKCa and TRPV2 were simultaneously 
suppressed. We suggest that Ca2+ entry through TRPV2 
activates the Ca2+-sensitive BKCa channel increasing the 
driving force of Ca2+ across TRPV2. We have presently 
no evidence about a formation of a physical complex 
between TRPV2 and BKCa channels but both were found 
in pseudopodia, supporting their functional association. 
Although we cannot exclude a participation of other 
Ca2+ channels, TRPV2 appears to be the major player for 
LL-37 induced migration in the three cell lines we have 
investigated. Our immunohistochemical studies on breast 
tumors show a significant correlation of LL-37 and TRPV2 
expression indicating a physiological relevance of their 
cooperation. ‘Transgenic expression of hCAP18/LL-37 
in MCF7 cells increased TRPV2 by a posttranscriptional 
mechanism, which may explain why both were found 
coexpressed in breast tumors.
Expression of TRP channels has been correlated 
with the aggressivity of multiple cancer forms, both in 
model systems [47] and in clinical investigations [48, 49]. 
Similarly LL-37 has been linked to development and 
progression of various cancer forms. Our results have 
shown a functional association between LL-37 and ion 
channels, which appears as a novel approach for research 
on cancer development and drafting of therapeutic 
strategies.
Figure 7: Mechanism proposed for the stimulatory activity of LL-37 on cell migration. LL-37 binds to the membranes 
of caveolae and pseudopodia (1), and activates PI3K/AKT signaling (2). AKT induces the recruitment of the TRPV2 channel (3) from 
intracellular vesicles to plasma membranes of pseudopodia. The increase of intracellular Ca2+ induced by TRPV2 is accompanied by K+ 
efflux through BKCa (4), which preserves the ion balance and helps to maintain the Ca2+ entry, which promotes cancer cell migration.
Oncotarget23795www.impactjournals.com/oncotarget
MATeRIALs AnD MeThoDs 
cell lines
MCF7, MDA-MB-435s and MDA-MB-231 cell 
lines were obtained from ATCC and grown in Dulbecco’s 
modified Eagle’s medium, supplemented with 5% fetal 
calf serum (Eurobio, Courtaboeuf, France). Cells were 
grown at 37°C in a humidity saturated atmosphere 
containing 5% CO2. 
For transgenic expression of hCAP18, MCF7 cells 
were transfected with a pIRES-EGFP expression vector 
[2] and selected with G418 at 400 µg/ml and by FACS 
sorting. 
Peptides, inhibitors and antibodies used in this 
study
Unmodified L- and D-peptides were synthesized 
and HPLC-purified to > 95% (GeneCust, Dudelange, 
Luxembourg, and GL Biochemicals, Shanghai, China). 
Sequences were: LLGDFFRKSKEKIGKEFKRIVQRIK 
DFLRNLVPRTES for LL-37, and RSLEGTDRFPFVRL 
KNSRKLEFKDIKGIKREQFVKIL for the scrambled 
control peptide [50]. LL-37-Asp26Ile (GL Biochemicals) 
was used to verify that modifications at position 26 did not 
affect the activity of this peptide. All experiments were 
performed at 10 µg/ml (2.2 µM) of peptides. Inhibitors 
and antibodies and the concentration used in this study are 
listed in supplementary Tables S3 and S4.
cell migration assay
Before cell migration assay, cells were starved 
24 h in DMEM BSA 0.1% and FCS 0.1% and were 
seeded (15 000 cells for MDA-MD-435, 15 000 for 
MDA-MB-231, 50 000 for MCF7) in the upper side of 
a migration chamber (Insert with Polyethylene filter with 
8 µm pores, Falcon BD Biosciences, Le Pont de Claix, 
France). The lower chamber was filled with DMEM BSA 
0.1% and FCS 0.1% added or not with LL-37 (10 µg/ml). 
After 4 h at 37°C for MDA-MB-231 and MDA-MB-435s 
cells, cells having migrated in the lower face of the filter 
were fixed with methanol, labelled with hematoxyline 
(Sigma-Aldrich, St. Quentin Fallavier, France) and 
counted. Given the lower migratory capacity of MCF7 
cells, their migration was performed over 14 hours. 
To highlight the pro-migratory effect of LL-37, results 
are normalized to migration of cells without LL-37. To 
highlight potential inhibitory effects of reagent or siRNA 
or inhibitors, results are normalized to migration of cells 
with LL-37.
Intracellular ca2+ measurements
Cells were seeded at 600 000 cells in 28 cm² tissue 
culture dishes 48 h before the experiment and kept in 
OptiMEM (Life Technologies, Saint Aubin, France) 
containing 0.2% BSA during 24 h. Cells were loaded with 
the ratiometric dye Fura2-AM (5 µM) (Thermo Scientific, 
Illkirch, France) at 37°C for 45 min, then detached with 
EDTA and centrifuged. Two protocols were available to 
follow intracellular Ca2+ concentration: for the first, cells 
were re-suspended in physiological saline solution (PSS) 
(NaCl 140 mM, KCl 4 mM, MgCl2 1 mM, HEPES 10 mM 
and Glucose 11.1 mM, pH 7.4) containing 2 mM Ca2+. 
This leads to measure total intracellular Ca2+ concentration 
variations. Fluorescence emissions of cell suspensions 
in a magnetically stirred cuvette were monitored 
in a spectrophotometer (F-2710 FL, Hitachi/VWR, 
Fontenay-sous-Bois, France). Pharmacological inhibitors 
(concentrations in Supplementary Table S4) were added at 
the beginning of the measurement, and after a stabilization 
period of 300 s (used as Ca2+ intracellular basal level), 
LL-37 was injected. Intracellular Ca2+ variations were 
evaluated using the fluorescence (510 nm) emission ratio 
at excitations at 340 and 380 nm. The basal ratio obtained 
for Ca2+ concentration was used as reference to normalize 
subsequent measurements after LL-37 application with or 
without inhibitors.
For the second protocol, which selectively monitors 
the import of extracellular Ca2+ across the plasma 
membrane, cells were suspended in PSS without Ca2+. 
LL-37 was added at the beginning of the measurement 
(used as basal level) and after 20 s 2 mM Ca2+ was applied. 
Intracellular Ca2+ concentration variations were detected 
as described above. In this protocol, inhibitors were 
incubated during loading with Fura2-AM, and additionally 
added at resuspension of the cells before the beginning of 
the measurement. 
Determination of cell membrane fluidity changes
Cells were kept in Optimem overnight, mechanically 
detached by flushing with DPBS (Lonza, Levallois-Perret, 
France). A suspension of 500 000 cells/ml in DPBS was 
incubated for 15 min at 37°C with 5 µM Laurdan (Sigma-
Aldrich), and fluorescence emissions were determined 
in the spectrophotometer as above, at an excitation at 
365 nm. The Generalized Polarisation (GP) value was 
determined as: GP = (em440−em490)/(em440+em490), em 
being the emission intensities at the indicated wavelengths 
[25].
Immunofluorescence labeling 
Cells were seeded in Lab-Tek chamber 8-well 
slides at 20 000 cells per well during 48 h. 24 h before 
treatment, cells were kept in OptiMEM, BSA 0.2%. Cells 
were washed with DPBS with Ca2+ and incubated with 
LL-37 10 µg/ml at room temperature. After 5 min, LL-37 
was removed, cells were fixed with DPBS containing 4% 
paraformaldehyde during 15 min at 4°C under agitation, 
and incubated with saturation solution (DPBS containing 
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50 mM NH4Cl and 3% BSA) or permeabilisation solution 
(DPBS, 50 mM NH4 Cl, 3% BSA 0.1% Tween 20) 
30 min at 4°C. Anti-LL-37 rabbit antibody (Osenses/
Ozyme, Fontenay-sous-Bois, France) was diluted in 
DPBS, 1% BSA at 1:500 and added on cells overnight 
at 4°C under agitation. Next, cells were incubated with 
secondary antibody coupled with green fluorescence 
dye CF488A (Biotium/Ozyme) at 1:2000 for 2 h. After 
staining with DAPI (Ref 32670, Sigma-Aldrich) at 1/5000 
for 2 min, samples were washed with DPBS and lamella 
were fixed with Fluorescent Mounting Medium (DAKO, 
Les Ulis, France). 
For the TRPV2 labeling protocol, cells were pre-
incubated or not with inhibitors during 45 min at 37°C. 
LL-37 or (D)-LL-37 were added during 5 min at room 
temperature. Anti TRPV2 rabbit antibodies (extracellular 
domain, Antibodies Online, Aachen, Germany) at 1:300 
and secondary antibodies coupled with CF488A at 1/200 
were used for labelling TRPV2 as described above. 
Cells were observed on a confocal microscope, at ×600 
magnification (Olympus Fluoview FV500 Laser Scanning 
Confocal Biological Microscope) and image acquisition 
was performed using Fluoview 500 v.5 software 
(Olympus, Tokyo, Japan).
In vitro and in cellulo fluorescence labeling of an 
azido-functionalized LL-37 
A modified peptide (LL-37-Asp26Anl) at 
which Asp26 had replaced by ω-azidonorleucine, was 
synthesized on a Prelude automated synthesizer (Protein 
technologies) starting from an aminomethyl PEGA resin 
(Novabiochem/Merck Millipore, Molsheim, France) and 
using standard Fmoc/t-butyl chemistry. N-Fmoc-ω-azido-
L-norleucine was prepared as described [51]. Standard 
trifluoroacetic acid-activated cleavage of the resin and 
removal of the side chains protecting groups was followed 
by purification of the peptide to > 99% purity by reverse 
phase HPLC. For fluorescence labelling, DBCO-Sulfo-
Cy5 (Jena Bioscience, Jena, Germany) was coupled 
to LL-37-Asp26Anl through a bioorthogonal strain-
promoted azide/alkyne cycloaddition (SPAAC) reaction 
according to the manufacturer's protocols, either before or 
after application of the peptide to the cells at 10 µg/ml. 
Coupling of the fluorochrome before or after treatment of 
the cells with functionalized LL-37 did not to influence its 
cellular localization (data not shown).
Confocal spectral imaging 
25000 cells were seeded on cover slides placed 
in 24-well plates for overnight. The medium was 
discarded and the cells were incubated for 30 min with 
Cy5-labelled modified LL-37 (10 µg/ml in DPBS) at 37°C 
and 5% CO2. After incubation, cells were washed thrice 
with fresh DPBS, put on a microscope glass slide, covered 
with a drop of DPBS and with a thin cover slide.
Fluorescence measurements were carried out using a 
low dispersion mode (grating 300 grooves/mm) of a laser-
scanning LabRam confocal microspectrometer (Horiba, 
Les Ulis, France). Cy5 fluorescence was excited with the 
632.8 nm line of a built-in air-cooled, He-Ne laser. The 
power on the samples was estimated to be below 150 µW; 
the acquisition time was 0.02 s per spectrum. No sample 
photodegradation was observed. Sample irradiation and 
collection of fluorescence spectra were performed through 
a × 50 LWD microscope objective (numerical aperture 
0.90; Olympus). The confocal whole aperture was adjusted 
to obtain ~0.8 µm lateral and 3.5 µm axial resolution.
For each cell analysis, an optical section (x–y 
plane) situated at half-thickness of the cell was scanned 
with a step of 0.8 µm and at each point a full fluorescence 
spectrum from 635 to 800 nm was recorded. That provided 
maps containing typically 625 spectra (25 × 25 points). 
Both acquisition and treatment of multispectral maps 
were performed with LabSpec software. Subcellular LL-
37 distribution maps were established via analysis of both 
the intensity and shape of Cy5 fluorescence spectra, as 
described [52]. Briefly, each experimental spectrum was 
fitted using the least-squares method to a sum of the two 
reference spectra of Cy5 where the shorter/longer position 
(maxima at 668/671 nm) corresponded respectively to 
a lower/higher polarity of the molecular environment 
of the fluorophore [21]. The fitting errors were below 
5% (typically 2–4%). These coefficients were used to 
generate the respective two-dimensional distribution maps 
over the cell. The results were averaged over 9–12 cells 
for each kind of treatment. The cellular autofluorescence 
was completely neglected, because of the absence of any 
significant fluorescence of the untreated cells under the 
conditions used. 
Immunogold labelling of cryosections according 
to Tokuyasu for immunoelectron microscopy [53] 
Cells were cultured in 175 cm2 flask at 80% 
confluence during 48 h. 24 h before treatment, cells were 
starved with OptiMEM containing 0.2% BSA. Cells were 
suspended in DPBS with Ca2+ and treated with LL-37 or 
not treated. After 5 min, PFA at 8% is added directly on 
suspended cells v/v to final concentration at 4% and cells 
were incubated 2 hours at room temperature stirring then 
washed in DPBS for 2 × 5 min and centrifuged at 2000 × g 
for 10 min. After removing the supernatant, cell pellets were 
included in gelatin 12% and infused with sucrose 2.3 M 
overnight at 4°C. 90 nm ultra-thin cryosections were 
made a −110°C on a LEICA UCT cryoultramicrotome. 
Sections were retrieved with Methylcellulose 2%/Sucrose 
2.3 M mixture (1:1) and collected onto formvar/carbon 
coated nickel grids. After removal of gelatine at 37°C, 
sections were incubated on drops of DPBS, 1% BSA 
and one hour on drops of DDPBS with 1:200 antibody 
anti-LL-37 (Osenses) or 1:100 antibody anti-TRPV2 
(Antibodies Online). After six washes of five minutes 
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each, grids were incubated on drops of DPBS containing 
1:30 gold-conjugated (6 nm) goat-anti-rabbit IgG (Aurion/
Biovalley, Nanterre, France). Grids were finally washed 
with six drops of DPBS (five minutes each), post-fixed in 
1% glutaraldehyde and rinsed with three drops of distilled 
water. Contrasting step was performed by incubating grids 
on drops of uranyl acetate 4%/methylcellulose 2% mixture 
(1:10). The sections were imaged in a transmission 
electron microscope at 100 kV (JEOL 1011).
Immunohistochemistry
For immunohistochemistry of cell lines,15 million 
cells were harvested, spun down, dehydrated and embedded 
in paraffin. Slide sections from cells and tumor samples 
were deparaffinized, rehydrated in 10 mM sodium citrate 
pH 6.0, and treated in a microwave oven (600 W) for 
3 × 10 min. After treatment with 3% of H2O2 for 5 min, 
slides were blocked in TBS/10% FCS for 30 min, then 
primary antibody was applied in TBS/0.1% TritonX100 
at 4°C. Antibodies and concentrations are listed in 
supplementary Table S3 The specificity of the TRPV2 
antibody was validated on MDA-MB-435s cells with/
without suppression of TRPV2 by RNA interference. 
Treatment with secondary antibody and development was 
performed with a commercial detection kit (Dako).
For immunohistochemistry on tumors, the study 
cohort included 101 female patients which consent was 
obtained prior to the study. The age median age was 
49 years (28 minimum and 71 maximum). They were 
treated at the university Hospital of Tours (France) and 
presented breast cancer proven by immunohistopathology. 
A pathologist with experience in breast disorders reviewed 
histology and staining on slides. The histological type of 
the cancers was all invasive with 82 ductal carcinomas 
(81, 2%), 7 lobular carcinomas (6.9%) and 12 carcinomas 
with other histotypes (11.9%) (such as cribriform, tubular, 
mucinous…). 81 carcinomas expressed oestrogen and/
or progesterone receptors (80,2%), 10 were classified as 
HER positive (9.9%) and 16 as triple negative phenotype 
(15.8%). TRPV2 and LL-37 labelling was performed as 
specified for cell lines (see above).
RnA interference
siRNAs used in this study are listed in 
supplementary Table S1. For TRPC1 and TRPV2, two 
additional control siRNAs were used against different 
target sites of the transcripts in initial experiments on 
intracellular Ca2+ and on cell migration, to verify the 
specificity of our observations. The silencing efficiency 
was monitored by qRT-PCR or Western Blot analysis 
and exceeded 70% for all siRNA. A scrambled siRNA 
(Qiagen) served in all experiments as a transfection 
control. 
Cell lines were transfected in suspension using 
Lipofectamine RNAiMax (Fisher Scientific) according to 
the manufacturer’s protocol, at a final siRNA concentration 
of 30 nM. Cells were then seeded in tissue culture dishes 
28 cm² at 750 000 cells per dish or 6-wells plates at 
250 000 cells per well (in culture medium). Experiments 
were performed 48 h after transfection. 
expression analysis by quantitative real-time 
polymerase chain reaction (qRT-PCR) 
Total RNA of MDA-MB-435s, MDA-MB-231 
or MFC-7 cells were extracted according to standard 
protocols with NucleoSpin®RNA II kit (Macherey-Nagel, 
Hoerdt, France), and reverse transcribed using RevertAid 
First Strand cDNA Synthesis Kit (Fermentas/Thermo 
Scientific). Gene quantifications were performed on 50 ng 
of cDNA using SYBR® Premix Ex Taq™ II (Tli RNaseH 
Plus, TAKARA/Ozyme) using MyiQ thermocycler (Bio-
Rad, Marnes-la-Coquette France). Primers (all from 
Sigma-Aldrich) were used at final concentration of 200 nM 
and temperature protocol was 10min start at 95°C, 
followed by 40 cycles of 15 s at 95°C, 30 s at 57°C and 30 s 
at 72°C. Relative gene expression levels were normalized 
to HPRT1 and calculated using the 2−DDCt method. Primers 
are listed in supplementary Table S3.
electrophysiological recordings
MDA-MB-435s cells were seeded at 10 000 cells 
per 35 mm Petri dish 48 h before the experiment and 
serum-starved in OptiMEM supplemented with 0.2% BSA 
during 24 h. Before measurement, extracellular culture 
medium was replaced by physiological saline solution PSS 
(140 mM NaCl, 4 mM KCl, 1 mM MgCl2, 2 mM CaCl2, 
0.33 mM NaH2PO4, 10 mM HEPES and 11.1 mM glucose, 
pH 7,4). Experiments were performed at room temperature 
using conventional whole-cell configuration as previously 
described [17]. Briefly, Patch-clamp experiments were 
performed with an Axopatch 200B patch-clamp amplifier 
(Axon Instruments, Wokingham, UK). Data are recorded 
with 1322-A Digidata converter (Axon Instruments) and 
pClamp software (v9.2, Axon Instruments) was used for 
generation of voltage commands, acquisition and analysis 
of whole-cell currents. Patch pipettes were pulled from 
borosilicate glass capillary (3–5 MΩ) by a stretcher 
(P-97 model, Sutter Instrumens, Cancale, France) and 
were filled with a intrapipette solution at pCa 6.4 (125 mM 
K-Glutamate, 20 mM KCl, 1 mM MgCl2, 1 mM Mg-ATP, 
0.7 mM CaCl2, 1 mM EGTA and 10 mM HEPES, pH 7.2). 
During experiments, the cell was continuously perfused 
with PSS or PSS containing LL-37 or/and inhibitors.
MDA-MB-435s whole-cell currents were measured 
using two different protocols. First, a current-voltage (I–V) 
protocol was performed and the membrane was clamped 
by steps from −90 at +80 mV during 500 ms with 10 mV 
increments. We next used a ramp protocol from −100 to 
+70 mV during 500 ms, from a holding potential of 0 mV 
and 4 s between each ramp. Currents (I) were normalized 
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to cell capacitance and expressed as densities of current 
(pA/pF). The conductance was estimated as a slope of the 
I–V curves around the inversed potential of cells. Current 
amplitudes were analyzed at 0 mV. The patch-clamp data 
were then analyzed using OriginPro software (OriginLab, 
Paris, France).
Western blot analysis 
Cells were rinsed in ice-cold DPBS before protein 
extraction with Sodium dodecylsulfate lysis buffer 
containing 1% β-mercaptoethanol, and heated 5 min at 
72°C. Western blot was essentially performed as described 
[3]. Samples were separated using electrophoresis gel at 
8% poly-acrylamide and transferred to nitrocellulose 
membrane (GE Healthcare), and incubated with primary 
antibody solutions overnight at 4°C. Antibodies and their 
dilutions are listed in supplementary Table S3. After 
incubation with HRP-coupled secondary antibodies and 
application of ECL advance solution (GE Healthcare/
Fisher Scientific) signals were recorded with a CCD 
camera (MF ChemiBIS, DNR Bio-imaging Systems, 
Jerusalem, Israel) and evaluated using Multi Gauge 
Software (v3.0, Fujifilm, Tokyo, Japan). For normalisation, 
filters were stripped with 200 mM glycine/HCl pH 2.5, 
and reprobed.
statistic analysis
The experiments were evaluated by Mann-Whitney 
and paired Wilcoxon statistics. Statistical significance is 
indicated in the figures with stars, *p < 0.05, **p < 0.01, 
***p < 0.001. The number n of measurements for the 
individual experiments is indicated in the figure legends. 
Results are displayed as mean ± SEM. The Chi-square test 
was used for comparison between immunohistochemical 
staining of LL-37 or TRPV2 and the characteristics of the 
101 carcinomas.
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